Emerging therapies have recently received approval for the treatment of MET exon 14 skipping non–small cell lung cancer (NSCLC). Further characterization of these therapies, such as tepotinib, is needed to identify patient subgroups most likely to derive benefit from these novel agents.

See related article by Le et al., p. 1117

You do not currently have access to this content.